Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma

Surgical Oncology Clinics of North America

Volumn 12, Issue 2, 2003, Pages 469-483

  Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DACTINOMYCIN; DOXORUBICIN; GAMMA INTERFERON; INDOMETACIN; MELPHALAN; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; META ANALYSIS; MOUSE; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; PARESTHESIA; REVIEW; SENSORY DYSFUNCTION; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TUMOR NECROSIS;

EID: 0037738635     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00012-7     Document Type: Review

References (64)

1. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clincopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-27.
2. Suit HD, Tepper JE. Impact of improved local control on survival in patients with soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1986;12:699-700.
3. Brennan MF, Shiu MH, Collin C, et al. Extremity soft tissue sarcomas. Cancer Treat Symp 1985;3:71-81.
4. Potter DA, Kinsella D, Gladstein E, et al. High grade soft tissue sarcomas of the extremities. Cancer 1986;59:190-205.
5. Stotter AT, A'Hearn RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990;65:1119-29.
6. Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991;67:2083-6.
7. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics, 1994. CA Cancer J Clin 1999; 9:8-26.
8. Suit HD, Proppe KH, Mankin HJ, Wood WC. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981;47:2269-74.
9. Eilber FR, Mirra JJ, Grant T, Weisenburger T, Morton DL. Is amputation necessary for sarcoma: a 7-year experiment with limb salvage. Ann Surg 1980;192:431-7.
10. Eilber FR, Morton DL, Eckhardt J, Grant T, Weisenburger T. Limb salvage for skeletal and soft-tissue sarcomas: multidisciplinary preoperative therapy. Cancer 1984;53:2579-84.
11. Shiu MH, Hilaris BS, Harrison LB, Brennan MF. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991; 21:1485-92.
12. Creech O, Krementz E, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
13. Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-63.
14. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma - effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227-33.
15. Eggermont AMM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996;26:335-49.
16. Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124-6.
17. Wieberdink K, Benckhuijsen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
18. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977;185(5):555-64.
19. Muchmore JH, Carter RD, Krementz ET. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review. Cancer Invest 1985;3:129-43.
20. Di Filippo F, Giannarelli D, Botti C, et al. Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcomas. Ann Oncol 1992;3:S71-S74.
21. Pommier RF, Moseley HS, Cohen J, et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 1988;155:667-71.
22. Klaase JM, Kroon BBR, Benckhuysen C, Van Geel AN, Albus-Lutter CHE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-21.
23. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-6.
24. McBride CM. Sarcomas of the limbs: result of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974;109:304-8.
25. Stehlin JS, de Ipolyi PD, Giovanella BC, Gutierrez AE, Anderson RF. Soft tissue sarcomas of the extremity: Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 1975;130:643-6.
26. Lethi PM, Stephens MH, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986;162:149-52.
27. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987;60:1703-7.
28. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
29. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
30. Asher AL, Mule JJ, Reichert CM, Shilone E, Rosenberg SA. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
31. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;476:2986-9.
32. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987;56:803-8.
33. Haranaka K, Sakurai A, Satomi N. Anti-tumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy or immunotherapy. J Biol Response Modif 1987;6:379-91.
34. Brouckaert PGG, Leroux-Rouls GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 1986;38:763-9.
35. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:50-62.
36. Eggermont AMM, Liénard D, Schraffordt Koops H, Van Geel AN, Hoekstra HJ, Lejeune FJ. Limb salvage by high dose tumor necrosis factor-alpha (TNF), gamma-interferon (IFN) and melphalan isolated limb perfusion (ILP) in patients with irresectable soft tissue sarcomas. Proc Am Soc Cin Oncol 1992;11:412.
37. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
38. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64; discussion 764-5.
39. Eggermont AMM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BBR, Gustafson P, et al. Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proceed ASCO 1999;11:497.
40. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80:995-7.
41. Vaglini M, Belli F, Ammatuna M, Inglese M, Manzi R, Prada A, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose TNF, gamma-IFN and melphalan. Cancer 1994;73:483-92.
42. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997;79:1129-37.
43. Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000;26:669-78.
44. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza M, Azzarelli A, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999; 86:1742-9.
45. Vrouenraets BC, Eggermont AMM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001;27:390-5.
46. Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405-12.
47. Stam TC, Swaak AJ, de Vries MR, ten Hagen TLM, Eggermont AMM. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage [in process citation]. Ann Surg Oncol 2000;4:268-75.
48. Elieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64-9.
49. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 1995;18:215-24.
50. Lienard D, Eggermont AMM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase 11 study. Melanoma Res 1999;9:491-502.
51. Olieman AF, Lienard D, Eggermont AMM, Kroon BBR, Lejeune FJ, Hoekstra HJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999;134:303-7.
52. Bickels J, Manusama ER, Gutman M, Eggermont AMM, Kollender Y, Abu-Abid S, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999;25:509-14.
53. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Synergistic antitumor effect of recombinant human tumor necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
54. Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumor approach. Eur J Surg Oncol 1996;22:152-7.
55. Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk L, Stavast J, Marquet RL, et al. Synergistic antitumor effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 1996;74:1908-15.
56. De Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM. Tumor necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
57. Van de Veen AH, Wilt de JHW, Eggermont AMM, van Tiel ST, ten Hagen TLM. TNF-α augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 2000; 82:973-80.
58. DeWilt JHW, Manusama ER, van Tiel ST, van IJken MGA, ten Hagen TLM, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumor necrosis factor-alpha and melphalan in rats. Br J Cancer 1999;80:161-6.
59. Seynhaeve ALB, de Wilt JHW, van Tiel SA, Eggermont AMM, ten Hagen TLM. Combination of actinomycin D with TNF-a in isolated limb perfusion results in improved tumor response in soft tissue sarcoma-bearing rats but is accompanied by severe dose limiting local toxicity. Br J Cancer 2002;86:1174-9.
60. Manusama ER, Nooijen PTGA, Stavast J, de Wilt JHW, Marquet RL, Eggermont AMM. Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcoma-bearing brown norway rats. J Surg Res 1998; 78:169-75.
61. DeWilt JHW, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve ALB, et al. Inhibition of nitric oxide synthesis by L-Name results in synergistic antitumor activity with melpahlan and tumor necrosis factor-alpha-based isolated limb. Br J Cancer 2000; 83:1176-82.
62. Milas M, Feig B, Yu D, Oriuchi N, Cromeens D, Ge T, et al. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 1997; 3:2197-203.
63. Roos de WK, de Wilt JHW, van der Kaaden ME, Manusama ER, de Vries MW, Bpit A, et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 2000;232:814-21.
64. De Wilt JHW, Bout A, Eggermont AMM, van Tiel ST, ten Hagen TLM, de Roos WK, et al. Adenovirus-mediated IL-3β gene transfer using isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther 2001;12:489-502.